Company.

Our products.

RevealAI-Lung is a computer-aided diagnostic application that reads the sub-visual radiomic features of a single lung nodule and returns a malignancy similarity score. It is cleared in six jurisdictions and delivered through the imaging platforms departments already run.

We characterize the lung nodule, put the result in the report, and integrate with the systems you already run. RevealAI-Lung is the first medical imaging AI software to achieve reimbursement within the European Union, and is reimbursed in the United States.

Leadership.

Select a name to read a short biography.

Chris WoodChief Executive Officer

Chris is a medical physicist with around thirty years in radiology, including a long tenure at Siemens. He founded Confirma, the first company to achieve FDA clearance for automated cancer detection in breast MR images, and Clario, whose workflow software now runs roughly a quarter of all radiology exams in the United States. Both were acquired. He leads RevealDx on the same premise that drove them: give radiologists better tools, and earlier diagnosis follows.

Michael Calhoun, PhDFounder and Chief Technology Officer

Michael founded RevealDx and designed the product and mSI^™ analysis. He studied computer science at Boston University, took a doctorate in neuroscience at the University of Basel, and was a postdoctoral fellow at the Mount Sinai School of Medicine before leading clinical research at Johns Hopkins and University Hospital Tübingen. He previously founded Sinq Systems and Mindshare Medical. The method RevealAI-Lung uses to characterize lung nodules is protected by U.S. Patent No. 10,255,997.

Lauren Nicola, MDChief Medical Officer

Lauren is a diagnostic radiologist and chief executive of Triad Radiology Associates. She chairs the American College of Radiology’s Reimbursement Committee, serves on its Economics Commission, and is a member of the ACR AI Advisory Group — which places her at the center of how imaging AI actually gets paid for. She advises RevealDx on clinical strategy and evidence.

David AustinVice President, Sales

David leads commercial strategy and sales at RevealDx. He has spent close to thirty years selling diagnostic imaging into radiology — as area vice president for Siemens Healthineers’ central zone service business, a $275M book, and as US director of sales for Hologic’s MRI and ultrasound divisions. More recently he has taken pre-commercial medical device companies to market, which is the stage RevealDx is at now.

Ryan Brevard, MDDirector of Clinical Programs

Ryan is board certified in emergency medicine and practiced for over twenty years in Portland, Oregon. He has advised RevealDx on the clinical application of mSI^™ for almost five years and now leads clinical programs, working with hospitals and radiology groups redefining their lung cancer pathways around newer technology. He brings the referring physician’s view of what a radiology report has to do to change a decision.

Medical advisors.

Practicing clinicians who advise on clinical evidence, program design and implementation.

Jay Finigan, MDPulmonary and Critical Care — National Jewish Health

Jay is Professor of Medicine in oncology, pulmonary and critical care at National Jewish Health, where he directs the Respiratory Centers of Excellence and is medical director of the lung cancer screening and lung nodule programs. A fellowship-trained pulmonologist, he treats lung nodules and lung cancer and researches lung cell biology.

Kim Sandler, MDCardiothoracic Radiology — Vanderbilt Health

Kim is Professor of Radiology and Radiological Sciences at Vanderbilt Health, where she directs the Vanderbilt Lung Screening Program. A cardiothoracic radiologist and clinician-scientist, she co-chairs the American College of Radiology’s Lung Cancer Screening Steering Committee. Her research combines machine learning with imaging and blood-based biomarkers to improve lung cancer risk prediction and early detection, and she works to bring women’s enrollment in lung screening toward what breast screening has achieved.

Medical advisors have a financial relationship with RevealDx.

Regulatory standing.

Manufacturer of record: Precision Medical Ventures, Inc. dba RevealDx, 1800 Westlake Avenue North, Suite 104, Seattle, WA 98109.

Investors and partners.

In August 2026, 4DMedical (ASX:4DX) announced a distribution agreement and a $3.4M strategic investment covering the United States, Europe, Australia and New Zealand. RevealAI-Lung is integrated into the contextflow platform and is operational at clinical sites across Europe. RevealDx is also supported by an extensive network of investors including industry leaders and prominent physicians.

RevealAI-Lung is accessible directly from existing PACS, and it can also take lung nodules from a third-party detection system and return results to PACS. Several imaging platforms deliver it as a component of their own software.

Contact.

General and media inquiries: info@reveal-dx.com
Technical and clinical support: support@reveal-dx.com
1800 Westlake Avenue North, Suite 104, Seattle, WA 98109